IP Library Granted Patent US 7,906,646
Granted Patent B2
US 7,906,646 · App. 12/483,781 · Granted Mar 15, 2011

Spirocyclic heterocyclic derivatives and methods of their use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,646
App. No.
12/483,781
Granted
Mar 15, 2011
Kind
B2
Abstract

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

Claims (5)

1. A compound of the following formula:

or a pharmaceutically acceptable salt or N-oxide thereof.

2. A compound according to claim 1 which is in the form of a pharmaceutically acceptable salt.

3. A compound according to claim 2 wherein the salt is a hydrochloride salt.

4. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →